Report : Europe Malaria Treatment Market Forecast to 2030 - Regional Analysis - by Treatment (Generic Drugs, Originators, Vaccines, and Others), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
At 27.0% CAGR, Europe Malaria Treatment Market is Projected to be Worth US$ 3,060.97 Million by 2030, says Business Market Insights
According to Business Market Insights' research, the Europe malaria treatment market was valued at US$ 451.69 million in 2022 and is expected to reach US$ 3,060.97 million by 2030, registering a CAGR of 27.0% from 2022 to 2030. Growing strategic initiatives by market players and increasing prevalence of malaria are among the critical factors attributed to the Europe malaria treatment market expansion.
A few major players operating in the malaria treatment market are increasingly focusing on the adoption of various strategies such as product innovations, launches, and approvals; R&D investments; and mergers and acquisitions in order to remain competitive. A few of these initiatives are mentioned below:
- In 2023, The R21/Matrix-M malaria vaccine is included in the WHO's list of prequalified vaccines. Following the recommendations of the Malaria Policy Advisory Group and the WHO Strategic Advisory Group of Experts (SAGE) on Immunization, the WHO recommended its introduction in October 2023 to prevent malaria in children. Prequalification is a requirement for UNICEF to purchase vaccinations and for Gavi, the Vaccine Alliance, to provide financial support for their deployment, which means that more children will have access to vaccines as a crucial tool in the fight against malaria.
- In December 2021, Zydus Cadila announced the plan to develop its antimalarial drug ZY19489 with Medicines for Malaria Venture, which received US FDA approval. According to the company, the Phase I trial of ZY19489 demonstrated a long half-life and the potential for a single-dose cure for malaria. In a separate malaria challenge trial, strong antimalarial activity was displayed after a single oral dose of ZY19489.
- In January 2021, GSK, PATH, and Bharat Biotech (BBIL) declared that a product transfer agreement was signed for the malaria vaccine RTS,S/AS01E. The agreement included transferring the manufacturing of the RTS,S antigen portion of the vaccine and granting a license for all rights related to the malaria vaccine to BBIL. GSK retains production of the vaccine adjuvant (AS01E) and supplies it to BBIL.
- In May 2020, ADVANZ PHARMA Corp. Limited acquired Correvio Pharma Corp, a specialty pharmaceutical company. Under the acquisition, ADVANZ PHARMA achieved an immediate and direct commercial presence in France, Germany, Italy, Spain, and the Benelux region.
Therefore, the abovementioned strategic initiatives by the market players are expected to provide growth opportunities for the malaria treatment market in the coming years.
On the contrary, availability of counterfeit antimalarial drugs followed by subsequent drug resistance hurdles the growth of Europe malaria treatment market.
Based on treatment, the Europe malaria treatment market is categorized into generic drugs, originators, vaccines, and others. The generic drugs segment held 42.7% share of Europe malaria treatment market in 2022, amassing US$ 192.93 million. It is projected to garner US$ 1,284.26 million by 2030 to expand at 26.7% CAGR during 2022-2030.
In terms of route of administration, the Europe malaria treatment market is bifurcated into oral and parenteral. The oral segment held 71.5% share of Europe malaria treatment market in 2022, amassing US$ 322.84 million. It is projected to garner US$ 2,158.80 million by 2030 to expand at 26.8% CAGR during 2022-2030.
By distribution channel, the Europe malaria treatment market is categorized into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. The direct tender segment held 45.2% share of Europe malaria treatment market in 2022, amassing US$ 204.33 million. It is projected to garner US$ 1,390.25 million by 2030 to expand at 27.1% CAGR during 2022-2030.
Based on country, the Europe malaria treatment market has been categorized into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that France captured 37.5% share of Europe malaria treatment market in 2022. It was assessed at US$ 169.45 million in 2022 and is likely to hit US$ 1,125.26 million by 2030, exhibiting a CAGR of 26.7% during 2022-2030.
Key players operating in the Europe malaria treatment market are Cipla Ltd, Sun Pharmaceutical Industries Ltd, Sanofi SA, GSK Plc, Novartis AG, Pfizer Inc, and Lupin Ltd, among others. - In May 2021, Novartis reaches milestone delivery of 1 billion courses of antimalarial treatment.
- In October 2022, Pfizer completes acquisition of global blood therapeutics.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com